-- 根據週一提交給澳洲證券交易所的文件，Nextdc（ASX：NXT）已從國內外領先銀行組成的銀團獲得18億澳元的新高級債務融資承諾。 文件顯示，融資完成後，該公司的優先債務總額將從64億澳元增加至82億澳元，截至6月30日，其備考流動資金將增加至約84億澳元。 文件還指出，這些資金將主要用於支持與近期新客戶合約相關的資本支出、正在進行的數據中心開發以及一般公司用途。
Related Articles
Asia
Telix Pharmaceuticals' Investigational Imaging Agent May Potentially Diagnose a Range of Kidney Cancers
Telix Pharmaceuticals' (ASX:TLX) investigational imaging agent TLX250-Px has the potential to help diagnose kidney cancers beyond just clear cell renal cell carcinoma, or ccRCC, the company said Tuesday, citing an independent analysis published in the European Urology scientific journal.The analysis of phase three trial data showed that positive PET scan findings were "highly predictive" of malignancy overall, including in non-clear cell renal cell carcinoma, with a reported positive predictive value of 98%, the company said."Essentially all false-positives for ccRCC in the ZIRCON study have now been shown to be other malignant kidney cancer subtypes, reducing the risk of overtreatment and further supporting clinical adoption," said Telix Group Chief Medical Officer David Cade.
$ASX:TLX
Asia
Huajin International Chairman, CEO Face Consumption Restriction Order
Huajin International (HKG:2738) said its chairman and chief executive were subject to a consumption restriction order due to the alleged nonpayment of amounts owed, according to a Hong Kong bourse filing Tuesday.The company's chairman Xu Songqing and chief executive Chen Chunniu have been subject to the consumption restriction order, effective Nov. 25.The case stems from the alleged non-payment of 130 million yuan by two of the company's units Jiangmen Huamu Metals and Jiangmen Huajin Metal Product, under a finance lease arrangement. As of April 30, 16.4 million yuan was still owed to the creditors.Both Xu and Chen have been negotiating with creditors to resolve the matter and the company expects to reach a settlement by the end of August.
$HKG:2738
Asia
Tata Chemicals' Consolidated Loss Widens in Fiscal Q4
Tata Chemicals' (NSE:TATACHEM, BOM:500770) consolidated attributable loss widened to 21.3 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 1.56 billion rupees a year ago.Loss per share grew to 83.68 rupees compared with a loss per share of 2.19 rupees a year earlier, the chemicals manufacturer said in a filing to the Indian bourses on Monday.Revenue from operations in fiscal Q4 declined to 34.4 billion rupees from 35.1 billion rupees a year ago. This was lower than the 34.8 billion rupees estimated by analysts polled by Visible Alpha.The company's board recommended a dividend of 11 rupees per share for the financial year ended March 31.
$BOM:500770$NSE:TATACHEM